Brain tumor drug safety under scrutiny: temozolomide liver risk study launched
NCT ID NCT07675070
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at how safe and effective temozolomide (brand name Amitzo) is for people with aggressive brain tumors (grade III and IV gliomas). Researchers are tracking 100 patients to see how often liver injury occurs and to monitor other side effects. The goal is to better understand the risks of this chemotherapy drug in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide (Amitzo)
What this could lead to
If successful, this study could confirm the safety profile of temozolomide for glioma patients, potentially guiding safer treatment protocols.
What could go wrong
This is an observational study with no control group, so results may not prove cause and effect. Liver injury is a known risk of temozolomide, and the study's small size limits general conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orchid Pharmed
RECRUITINGTehran, Iran
Contact Phone: •••-•••-•••• Email: •••••@•••••